Short Term Rating on Endologix (ELGX)

Endologix (ELGX) : 8 analysts are covering Endologix (ELGX) and their average rating on the stock is 1.13, which is read as a Strong Buy. 7 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Endologix (ELGX) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Endologix (ELGX) : The highest short term price target forecast on Endologix (ELGX) is $17 and the lowest target price is $15. A total of 7 equity analysts are currently covering the company. The average price of all the analysts is $15.93 with a standard deviation of $0.61.

For the current week, the company shares have a recommendation consensus of Buy.


Endologix (NASDAQ:ELGX): The stock opened at $14.03 on Tuesday but the bulls could not build on the opening and the stock topped out at $14.50 for the day. The stock traded down to $13.81 during the day, due to lack of any buying support eventually closed down at $13.85 with a loss of -1.63% for the day. The stock had closed at $14.08 on the previous day. The total traded volume was 1,426,788 shares.

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Companys products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Companys EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.